Skip to main content
. Author manuscript; available in PMC: 2019 Jan 20.
Published in final edited form as: J Proteome Res. 2017 Aug 8;16(9):3266–3276. doi: 10.1021/acs.jproteome.7b00245

Table 3.

Summary of IHC Analyses

candidate biomarker relative intensity ± STDEV in NSCLC (N = 86) relative intensity ± STDEV in benign nodule (N = 63) P value

  ALOX5 0.04 ± 0.19 1.90 ± 0.79 <0.001
  ALOX5AP 0.00 ± 0.00 0.93 ± 0.71 <0.001
  ITGAX 0.00 ± 0.00 2.15 ± 0.81 <0.001
  SLC2A3 0.46 ± 0.81 1.59 ± 0.69 <0.001
  CEACAM6 1.47 ± 0.95 0.20 ± 0.61 <0.001
  CRABP2 1.76 ± 0.89 1.24 ± 0.72 0.004
  LAD1 0.58 ± 0.56 0.34 ± 0.43 0.054
  CD4 memb 6.8 ± 5.2 18.3 ± 14.3 <0.001
  CD8 memb 15.0 ± 11.0 24.4 ± 10.7 <0.001
  FOXP3 nuc 21.0 ± 11.0 30.0 ± 16.0 <0.001